Novartis has submitted NVA237, the company’s new treatment for chronic obstructive pulmonary disease, for approval in Japan.
The drug, which was submitted for European approval in September 2011 under the brand name Seebri Breezhaler, is a long-acting muscarinic antagonist designed to be taken once-daily.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Novartis originally licensed the drug from Japanese pharmaceutical company Sosei and UK-based Vectura in April 2005.
Novartis last week signed Eisai as a co-promoter of the drug should it receive Japanese approval.
